U.S. markets closed
  • S&P Futures

    4,273.50
    -3.25 (-0.08%)
     
  • Dow Futures

    33,953.00
    -10.00 (-0.03%)
     
  • Nasdaq Futures

    13,474.75
    -18.50 (-0.14%)
     
  • Russell 2000 Futures

    1,990.20
    +1.10 (+0.06%)
     
  • Crude Oil

    88.04
    -0.07 (-0.08%)
     
  • Gold

    1,779.40
    +2.70 (+0.15%)
     
  • Silver

    19.65
    -0.08 (-0.41%)
     
  • EUR/USD

    1.0185
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    2.8930
    +0.0690 (+2.44%)
     
  • Vix

    19.90
    +0.21 (+1.07%)
     
  • GBP/USD

    1.2050
    -0.0002 (-0.01%)
     
  • USD/JPY

    134.8860
    -0.2040 (-0.15%)
     
  • BTC-USD

    23,456.71
    -540.13 (-2.25%)
     
  • CMC Crypto 200

    557.83
    -14.99 (-2.62%)
     
  • FTSE 100

    7,515.75
    -20.31 (-0.27%)
     
  • Nikkei 225

    28,984.56
    -238.21 (-0.82%)
     

Credit Suisse Initiates Corteva Coverage, Sees Sharp Upside

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Credit Suisse analyst John Roberts initiated coverage of Corteva Inc (NYSE: CTVA) with an Outperform rating and a price target of $68, implying an upside of 34%.

  • The analyst compares CTVA with its peers and says that CTVA is a leading seed producer. He adds that CTVA is also replacing in-licensing expenses with new in-house traits. Additionally, CTVA pension liabilities are declining as interest rates rise.

  • Roberts states that CTVA is one of only five major global pesticide producers. Pricing over time is driven primarily by a mix of improvements from new products, and CTVA spends ~8% of sales on R&D – among the highest in his coverage.

  • CTVA was created from a merger of Dow & DuPont's agriculture units. DuPont's legacy glyphosate trait in-licensing agreement will be rolling off, and Dow's new Enlist trait is ramping to replace the in-licensed Xtend trait, noted the analyst.

  • Roberts says that the key risks to the downside include new product failures/recall, a significant drop in farm profitability, or a major decline in interest rates.

  • Price Action: CTVA shares are trading lower by 2.64% at $50.60 on the last check Thursday.

  • Photo Via Company

Latest Ratings for CTVA

Date

Firm

Action

From

To

Feb 2022

Keybanc

Maintains

Overweight

Nov 2021

Morgan Stanley

Maintains

Overweight

Nov 2021

Keybanc

Maintains

Overweight

View More Analyst Ratings for CTVA

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.